Key result
Saralasin infusion reduced blood pressure only in hypertensive patients with abnormally elevated basal plasma renin and angiotensin II levels, with a more marked reduction after sodium depletion.
Why the study?
Does saralasin infusion reduce blood pressure and alter the renin-angiotensin-aldosterone system in normal and hypertensive subjects?
Does saralasin infusion reduce blood pressure and alter the renin-angiotensin-aldosterone system in normal and hypertensive subjects?
Saralasin infusion demonstrates that renin and angiotensin II play a direct role in maintaining hypertension in patients with elevated basal plasma renin.
Answers are grounded in this paper and cite their sources.
Limits saralasin to high-renin cases; leaves open whether modern RAS inhibitors benefit similar patients.
Blood pressure reduction with saralasin infusion was seen only in hypertensive patients with abnormally elevated basal plasma renin and angiotensin II levels, and after sodium depletion the reduction in blood pressure was more marked. In normal subjects, and in hypertensives with plasma renin and angiotensin II levels within the normal range, there was no marked fall in blood pressure across saralasin infusion regardless of the sodium status of the individual. Plasma aldosterone concentration fell during saralasin infusion in those subjects with high baseline renin and angiotensin II levels. This fall occurred in the sodium replete and deplete states. In the normal subjects, and those hypertensives with normal plasma renin levels, there was no fall in aldosterone in the sodium replete state. However, after sodium depletion the expected rise in aldosterone was abolished during saralasin infusion, the plasma aldosterone falling to within the normal sodium replete range, rising again after the saralasin infusion was stopped. This study supports the concept of a direct role for renin and angiotensin II in the maintenance of hypertension in those subjects with elevated basal plasma renin. Plasma aldosterone would appear to be controlled, at least in part, by the prevailing plasma angiotensin II level in those subjects with elevated basal levels of angiotensin II; that is in high renin hypertensives, and in normal subjects and normal renin hypertensives who are sodium deplete.
No takes yet. Share an insight, caveat, or question.
Brown et al. (1976) studied Hypertension. Saralasin infusion vs. Baseline / Normal subjects / Normal renin hypertensives was evaluated on Blood pressure and plasma aldosterone concentration. Saralasin infusion reduced blood pressure only in hypertensive patients with abnormally elevated basal plasma renin and angiotensin II levels, with a more marked reduction after sodium depletion.
Synapse has enriched 10 related papers. Consider them for comparative context: